Intermuscular fat: a review of the consequences and causes.

Addison O, Marcus RL, Lastayo PC, Ryan AS. · 2014

Read Intermuscular fat: a review of the consequences and causes. by Addison O, Marcus RL, Lastayo PC, Ryan AS. (2014) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc3910392.txt.

Introduction

Odessa Addison, Robin L. Marcus, Paul C. LaStayo, and Alice S. Ryan review fat stored between muscles in the International Journal of Endocrinology in 2014. Called intermuscular adipose tissue, this fat grows with age and illness. The review starts from a puzzle: older adults lose strength faster than they lose muscle, so something besides muscle size must be at work.

Higher levels of this fat predict weaker muscles and poorer mobility in older adults and in people after stroke or spinal cord injury, and in diabetes and lung disease. The fat is also linked to insulin resistance, a step toward diabetes. The authors weigh what causes the fat to build up and what treatments might slow or reverse it.

Catalog record

CREATORAddison O, Marcus RL, Lastayo PC, Ryan AS.
YEAR2014
COLLECTIONPAPERS
FORMATTXT
FILE SIZE58 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC3910392

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Intermuscular Fat: A Review of the Consequences and Causes By Odessa Addison, Robin L. Marcus, Paul C. LaStayo, Alice S. Ryan Published in: International Journal of Endocrinology DOI: 10.1155/2014/309570 ABSTRACT Muscle's structural composition is an important factor underlying muscle strength and physical function in older adults. There is an increasing amount of research to support the clear disassociation between the loss of muscle lean tissue mass and strength with aging. This disassociation implies that factors in addition to lean muscle mass are responsible for the decreases in strength and function seen with aging. Intermuscular adipose tissue (IMAT) is a significant predictor of both muscle function and mobility function in older adults and across a wide variety of comorbid conditions such as stroke, spinal cord injury, diabetes, and COPD. IMAT is also implicated in metabolic dysfunction such as insulin resistance. The purpose of this narrative review is to provide a review of the implications of increased IMAT levels in metabolic, muscle, and mobility function. Potential treatment options to mitigate increasing levels of IMAT will also be discussed. 1. INTRODUCTION The unique ability of adipose tissue to expand throughout life and release a host of chemical messengers makes adipose not only a distinctive tissue but also the largest endocrine organ in the body [1]. In the last twenty years, a rapid expansion of our understanding of this unique organ has occurred. Once thought to be an inert storage depot for excess calories, important only to energy homeostasis, we now know that adipose tissue expresses and secretes a multitude of hormones and proinflammatory cytokines thereby acting in an autocrine, paracrine, and endocrine manner signaling the heart, musculoskeletal, central nervous, and metabolic systems [1–3]. Not all adipose depots are alike. Recent studies have suggested that the location [4–8] and type [9] of excess adipose tissue, rather than simply total body adiposity, may be important in the systemic increase of circulating cytokines and the rise in metabolic diseases such as diabetes [9–14] (for a more complete review of the types and roles of adipose tissue, see Wronska 2012 and Stehno-Bittel 2008) [1, 9]. Adipose tissue stored in subcutaneous depots, particularly in the gluteal-femoral region, is a negative predictor of metabolic syndrome and is cardioprotective [4–7, 15, 16]. However, adipose tissue stored in ectopic locations outside of the subcutaneous tissue such as in the muscle, liver, and abdominal cavity is linked with chronic inflammation [10, 17–19], impaired glucose tolerance [4–6, 20, 21], increased total cholesterol [8, 16, 22], and decreased strength and mobility in older adults [23–31]. Advancing age results in a redistribution of fat depots, despite stable or decreasing overall fat, with adipose storage sites changing from subcutaneous locations to the more harmful ectopic locations [3, 32, 33]. In particular, intermuscular adipose tissue (IMAT), an ectopic fat depot found beneath the fascia and within the muscles, may be of specific interest to rehabilitation professionals. IMAT has been studied in a variety of individuals with metabolic [5, 6, 8, 14, 28, 34–36], orthopedic [37, 38], and neurologic [39, 40] conditions commonly seen in rehabilitative settings. High levels of IMAT are associated with insulin resistance [5, 6, 8, 14, 28, 34–36], a loss of strength [23–31], and mobility dysfunction [23, 41–43]. High levels of IMAT can be found in many patient populations, including, but not restricted to, the paraspinal muscles of individuals with chronic back pain [37, 38] and the locomotor muscles of individuals diagnosed with HIV [44], spinal cord injury [39], CVA [40], diabetes [6], and COPD [45]. Furthermore, older adults with increased IMAT levels in the locomotor muscles are known to experience increased levels of muscle weakness, decreased mobility function [23, 41–43], and an increased risk of future mobility limitation [42, 43]. IMAT has potential clinical implications that rehabilitation professionals should recognize and attempt to manage in rehabilitation settings when working with older adults and those with diseases and disabilities associated with IMAT. The purpose of this narrative review is to inform rehabilitation professionals about the potential metabolic, muscle, and mobility associations of increased IMAT in the locomotor muscles of adults. This review will focus on three areas. First, the definition and measurement of IMAT will be presented; second, the implications of increased locomotor muscle IMAT in metabolism, muscle strength, and mobility will be reviewed; and third, recommendations for future research and treatment for adults with increased levels of IMAT will be made. Literature targeted for this review included peer reviewed cross-sectional, longitudinal, epidemiologic, and clinical studies in adult humans. 2. DEFINITIONS AND MEASUREMENTS OF IMAT IMAT has been referred to in the literature by a variety of names and definitions including myostasis, intermuscular fat, intramuscular fat, and low density lean tissue. Intermuscular fat is typically the broadest definition of fatty infiltration in the muscle referring to storage of lipids in adipocytes underneath the deep fascia of muscle. This includes the visible storage of lipids in adipocytes located between the muscle fibers (also termed intramuscular fat) and also between muscle groups (literally intermuscular) [46] (See Figure 1). While not frequently isolated as a separate fat depot by itself, there also exists a smaller group of lipids stored within the muscle cells themselves known as intramyocellular lipids or IMCL; IMCL has been reviewed extensively elsewhere [47]. Increased levels of IMCL are found both in obese insulin resistant individuals and in highly trained endurance athletes; these paradoxical findings have led to the conclusion that lipids stored within muscle cells are not always harmful to the cell [47]. For the remainder of this review, the term IMAT will refer to any measure of fat beneath the deep fascia of the thigh, not including studies that have used methods that independently quantify IMCLs (i.e., histochemical or spectroscopic methods). IMAT is most commonly measured via computed tomography (CT) or magnetic resonance imaging (MRI). While IMAT has been quantified in numerous studies, it is not yet routinely measured or quantified in clinical imaging studies. CT scans have been extensively used to quantify IMAT in numerous studies [5, 6, 10, 14, 20, 23, 28, 40, 42, 43, 48–52] and were first described by Kelley et al. in 1991 [53]. CT is a fast imaging method that utilizes X-rays for an indirect measurement of IMAT based on the tissue density of an area. On a continuum of density where bone is the most dense and fat is the least dense, lean muscle mass falls between these two extremes. Lean tissue seen on a CT scan can be further divided into areas of high-density lean tissue and areas of low-density lean tissue. High-density lean is an area where little fatty infiltration occurs, and low-density lean tissue is an area where increased levels of adipocytes are found between and within muscle fibers and result in decreased density on CT scan. An individual with a higher proportion of low-density lean is assumed to have increased levels of both IMCL and IMAT. If the density of a muscle increases, or the area of low-density lean decreases after an exercise program, it is presumed that the exercise program has resulted in a loss of both IMCL and IMAT. With MRI, direct measurements of IMAT [46] can occur without the use of harmful radiation; therefore, MRI is increasingly used

Read the complete text